|
11.
|
|
12 p, 1.1 MB |
Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials
/
González-Gil, Celia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Morgades, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Lopes, Thaysa (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fuster-Tormo, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
García-Chica, Jesús (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zhao, Ran (Cleveland Clinic) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Torrent Catarineu, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Díaz-Beyá, Marina (Hospital Clínic i Provincial de Barcelona) ;
Coll, Rosa (Institut Català d'Oncologia) ;
Hermosín, Lourdes (Hospital de Jerez) ;
Mercadal, Santiago (Hospital Duran i Reynals-ICO (Hospitalet del Llobregat)) ;
González-Campos, José (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Artola, Teresa (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Vall-Llovera, Ferran (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Tormo, Mar (Instituto de Investigación Sanitaria (València)) ;
Gil-Cortés, Cristina (Hospital General de Alicante (Alicante)) ;
Barba, Pere (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Novo, Andrés (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Ribera Salas, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bernal, Teresa (Hospital Universitario Central de Asturias) ;
de Ugarriza, Paula López (Hospital Universitario Central de Asturias) ;
Queipo, María-Paz (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Martínez-Sánchez, Pilar (Hospital Universitario 12 de Octubre (Madrid)) ;
Giménez, Alicia (Hospital Universitario 12 de Octubre (Madrid)) ;
González-Martínez, Teresa (Hospital Universitario de Salamanca) ;
Cladera, Antonia (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Cervera, José (Hospital Universitari i Politècnic La Fe (València)) ;
Fernández-Martín, Rosa (Hospital Universitario Insular de Gran Canaria) ;
Ardaiz, María Ángeles (Complejo Hospitalario de Navarra) ;
Vidal, María Jesús (Complejo Hospitalario de León) ;
Baena, Ángela (Complejo Hospitalario de Jaén) ;
López-Bigas, Nuria (Institut de Recerca Biomèdica (Barcelona)) ;
Bigas Salvans, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Maciejewski, Jaroslaw (Taussig Cancer Institute) ;
Orfao, Alberto (Universidad de Salamanca) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Genescà, Eulàlia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Genetic information has been crucial to understand the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) at diagnosis and at relapse, but still nowadays has a limited value in a clinical context. [...]
2022 -  10.3324/haematol.2022.281196
Haematologica, Vol. 108 (november 2022) , p. 969-980
|
|
|
12.
|
|
12 p, 927.8 KB |
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
/
Kwon, Mi (Hospital General Universitario Gregorio Marañón) ;
Iacoboni, Gloria (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Reguera-Ortega, Juan Luis (Instituto de Biomedicina de Sevilla) ;
Corral, Lucía López (Instituto de Investigación Biomédica de Salamanca) ;
Morales, Rafael Hernani (Hospital Clínic Universitari (València)) ;
Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ;
Guerreiro, Manuel (Hospital Universitari i Politècnic La Fe (València)) ;
Caballero, Ana Carolina (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Domínguez, María Luisa Guerra (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Pina, Jose Maria Sanchez (Hospital Universitario 12 de Octubre (Madrid)) ;
Mussetti, Alberto (Institut Català d'Oncologia) ;
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bastos, Mariana (Hospital General Universitario Gregorio Marañón) ;
Catala, Eva (Vall d'Hebron Institut d'Oncologia) ;
Delgado, Javier (Instituto de Biomedicina de Sevilla) ;
Henriquez, Hugo Luzardo (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Sanz, Jaime (Hospital Universitari i Politècnic La Fe (València)) ;
Calbacho, Maria (Hospital Universitario 12 de Octubre (Madrid)) ;
Bailén, Rebeca (Hospital General Universitario Gregorio Marañón) ;
Carpio Segura, Cecilia del Carmen (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Ribera Santasusana, Jose Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sureda, Anna (Institut Català d'Oncologia) ;
Briones Meijide, Javier (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Hernandez-Boluda, Juan Carlos (Hospital Clínic Universitari (València)) ;
Cebrián, Nuria Martínez (Hospital Clínic i Provincial de Barcelona) ;
Martin, Jose Luis Diez (Universidad Complutense de Madrid) ;
Martín, Alejandro (Instituto de Investigación Biomédica de Salamanca) ;
Barba, Pere (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. [...]
2022 - 10.3324/haematol.2022.280805
Haematologica, Vol. 108 (january 2023) , p. 110-121
|
|
|
13.
|
|
5 p, 310.2 KB |
Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols
/
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Morgades, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Gonzalez-Campos, Jose (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Torrent Catarineu, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gil, Cristina (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Bernal, Teresa (Hospital Universitario Central de Asturias) ;
Tormo, Mar (Hospital Clínic Universitari (València)) ;
Mercadal, Santiago (Hospital Duran i Reynals (Hospitalet del Llobregat)) ;
Novoa, Sandra (Hospital Universitari Vall d'Hebron) ;
Garcia Cadenas, Irene (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Queipo de Llano, M. Paz (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Cervera, Marta (Hospital Universitari Joan XXIII de Tarragona) ;
Coll, Rosa (Hospital Universitari de Girona Doctor Josep Trueta) ;
Bermúdez, Arancha (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Amigo, María-Luz (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Monsalvo, Silvia (Hospital General Universitario Gregorio Marañón) ;
Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Garcia-Boyero, Raimundo (Hospital General Universitari de Castelló) ;
Novo, Andres (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Hernandez Rivas, Jesús Maria (Hospital Universitario de Salamanca) ;
Cladera, Antonia (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Martinez-Sanchez, Pilar (Hospital Universitario 12 de Octubre (Madrid)) ;
Serrano, Josefina (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Artola, Maria Teresa (Donostia Unibertsitate Ospitalea) ;
Soria, Beatriz (Hospital Universitario de Canarias (La Laguna)) ;
Abella Monreal, Eugenia (Hospital del Mar (Barcelona, Catalunya)) ;
Vall-Llovera, Ferran (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Bergua Burgues, Juan Miguel (Hospital San Pedro de Alcántara) ;
Herrera, Pilar (Hospital Universitario Ramon y Cajal (Madrid)) ;
Barrios, Daniel (Hospital Regional Universitario de Málaga) ;
Ribera, Jose-Maria (Universitat Autònoma de Barcelona. Departament de Medicina)
2022 - 10.1097/HS9.0000000000000810
HemaSphere, Vol. 7 (december 2022)
|
|
|
14.
|
|
7 p, 1.3 MB |
Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)
/
Genescà, Eulàlia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Morgades, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
González-Gil, Celia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fuster-Tormo, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Haferlach, Claudia (MLL Munich Leukemia Laboratory) ;
Meggendorfer, Manja (MLL Munich Leukemia Laboratory) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Gil, Cristina (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Coll, Rosa (Hospital Universitari de Girona Doctor Josep Trueta) ;
Moreno, María-José (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Martínez-Carballeira, Daniel (Hospital Universitario Central de Asturias) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Vives Polo, Susana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ribera, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-Campos, José (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Díaz-Beyá, Marina (Hospital Clínic i Provincial de Barcelona) ;
Mercadal, Santiago (Hospital Duran i Reynals (Hospitalet del Llobregat)) ;
Artola, Maria Teresa (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Cladera, Antonia (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Tormo, Mar (Hospital Clínic Universitari (València)) ;
Bermúdez, Arancha (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Vall-Llovera, Ferran (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Martínez-Sánchez, Pilar (Hospital Universitario 12 de Octubre (Madrid)) ;
Amigo, María-Luz (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Monsalvo, Silvia (Hospital General Universitario Gregorio Marañón) ;
Novo, Andrés (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Cervera, Marta (Hospital Universitari Joan XXIII de Tarragona) ;
García-Guiñon, Antonio (Hospital Arnau de Vilanova (València)) ;
Ciudad Pizarro, Juana (Instituto de Investigación Biomédica de Salamanca) ;
Cervera, José (Hospital Universitari i Politècnic La Fe (València)) ;
Hernández Rivas, Jesús María (Hospital Clínico Universitario (Salamanca)) ;
Granada, Isabel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Haferlach, Torsten (MLL Munich Leukemia Laboratory) ;
Orfao, Alberto (Instituto de Investigación Biomédica de Salamanca) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. [...]
2021 - 10.1016/j.leukres.2021.106612
Leukemia Research, Vol. 109 (october 2021) , p. 106612
|
|
|
15.
|
|
5 p, 765.8 KB |
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
/
Iacoboni, Gloria (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Rejeski, Kai (Department of Medicine III, University Hospital, LMU Munich, Munich, Germany) ;
Villacampa Javierre, Guillermo (Vall d'Hebron Institut d'Oncologia) ;
van Doesum, Jaap A. (Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands) ;
Chiappella, Annalisa (Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy) ;
Bonifazi, Francesca (IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli", Bologna, Italy) ;
López Corral, Lucia (Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain) ;
van Aalderen, Michiel (Department of Hematology, Amsterdam University Medical Centers, Cancer Center Amsterdam, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands) ;
Kwon, Mi (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Martínez-Cibrian, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Bramanti, Stefania (Istituto Clinico Humanitas IRCCS, Rozzano, Italy) ;
Reguera-Ortega, Juan Luis (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Camacho-Arteaga, Lina (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Schmidt, Christian (Department of Medicine III, University Hospital, LMU Munich, Munich, Germany) ;
Marín-Niebla, Ana (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Kersten, Marie José (Department of Hematology, Amsterdam University Medical Centers, Cancer Center Amsterdam, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands) ;
Martín García-Sancho, Alejandro (Instituto de Investigación Biomédica de Salamanca) ;
Zinzani, Pier Luigi (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy) ;
Corradini, Paolo (Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy) ;
van Meerten, Tom (Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands) ;
Subklewe, Marion (Department of Medicine III, University Hospital, LMU Munich, Munich, Germany) ;
Barba, Pere (Universitat Autònoma de Barcelona. Departament de Medicina)
2022 - 10.1182/bloodadvances.2021006922
Blood advances, Vol. 6 (june 2022) , p. 3606-3610
|
|
|
16.
|
|
7 p, 884.3 KB |
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
/
Rejeski, Kai (German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany) ;
Burchert, Andreas (Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany) ;
Iacoboni, Gloria (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Sesques, Pierre (Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France) ;
Fransecky, Lars (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
Bücklein, Veit (Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany) ;
Trenker, Corinna (Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany) ;
Hernani, Rafael (Hospital Clínic Universitari (València)) ;
Naumann, Ralph (Medical Department III-Hematology and Oncology, St. Marien-Krankenhaus Siegen, Siegen, Germany) ;
Schäfer, Jonas (Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany) ;
Blumenberg, Viktoria (German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany) ;
Schmidt, Christian (Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany) ;
Sohlbach, Kristina (Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany) ;
von Bergwelt-Baildon, Michael (German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany) ;
Bachy, Emmanuel (Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France) ;
Barba, Pere (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Subklewe, Marion (German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany)
2022 - 10.1182/bloodadvances.2022007776
Blood advances, Vol. 6 (august 2022) , p. 4719-4725
|
|
|
17.
|
|
1.6 MB |
Characterization of a Cytomegalovirus-Specific T Lymphocyte Product Obtained Through a Rapid and Scalable Production Process for Use in Adoptive Immunotherapy
/
Grau-Vorster, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
López-Montañés, María (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Cantó Puig, Ester (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Vives Armengol, Joaquim (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Oliver-Vila, Irene (Cell Therapy Service, Banc de Sang i Teixits) ;
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Querol, Sergi (Cell Therapy Service, Banc de Sang i Teixits) ;
Rudilla, Francesc (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Immunosuppressed patients are susceptible to virus reactivation or de novo infection. Adoptive immunotherapy, based on virus-specific T lymphocytes (VST), can prevent or treat viral diseases. However, donor availability, HLA-compatibility restrictions, high costs, and time required for the production of personalized medicines constitute considerable limitations to this treatment. [...]
2020 - 10.3389/fimmu.2020.00271
Frontiers in immunology, Vol. 11 (february 2020)
|
|
|
18.
|
|
6 p, 158.9 KB |
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols
/
Ribera Salas, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Morgades, Mireia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González, T. (Universidad de Salamanca) ;
Ciudad Pizarro, Juana (Centro de Investigación Biomédica en Red de Cáncer) ;
Such, Esperanza (Hospital Universitari i Politècnic La Fe (València)) ;
Calasanz, M.J (Universidad de Navarra) ;
Mercadal, Santiago (Institut Català d'Oncologia) ;
Coll, Rosa (Hospital Universitari de Girona Doctor Josep Trueta) ;
González-Campos, José (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Tormo, M. (Hematology Department. Hospital Clínico Universitario) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Gil, Cristina (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Cervera, Marta (Hospital Universitari Joan XXIII de Tarragona) ;
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Costa, D. (Hospital Clínic i Provincial de Barcelona) ;
Ayala, Rosa (Hospital Universitario 12 de Octubre (Madrid)) ;
Bermúdez, Arancha (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Orfao, Alberto (Centro de Investigación Biomédica en Red de Cáncer) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBX1) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. [...]
2021 - 10.1111/bjh.17844
British Journal of Haematology, 2021
|
|
|
19.
|
|
|
20.
|
|
10 p, 1.3 MB |
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission : analysis from CALGB 10403 and the CIBMTR
/
Wieduwilt, Matthew J. (University of California) ;
Stock, Wendy (University of Chicago Medicine) ;
Advani, Anjali (Cleveland Clinic) ;
Luger, Selina (University of Pennsylvania Medical Center) ;
Larson, Richard A. (University of Chicago Medicine) ;
Tallman, Martin (Memorial Sloan Kettering Cancer Center. Leukemia Service, Department of Medicine) ;
Appelbaum, Frederick (Fred Hutchinson Cancer Research Center) ;
Zhang, Mei-Jie (Medical College of Wisconsin. Division of Biostatistics) ;
Bo-Subait, Khalid (Medical College of Wisconsin) ;
Wang, Hai-Lin (Medical College of Wisconsin) ;
Bhatt, Vijaya Raj (University of Nebraska Medical Center) ;
Dholaria, Bhagirathbhai (Vanderbilt University Medical Center) ;
Eapen, Mary (Medical College of Wisconsin) ;
Hamadani, Mehdi (Medical College of Wisconsin) ;
Jamy, Omer (University of Alabama at Birmingham) ;
Prestidge, Tim (Starship Children's Hospital (Auckland, Nova Zelanda)) ;
Pulsipher, Michael (Children's Hospital Los Angeles Cancer) ;
Ritchie, David (Peter MacCallum Cancer Centre) ;
Rizzieri, David (Duke University) ;
Sharma, Akshay (St. Jude Children's Research Hospital (Memphis, Estats Units d'Amèrica)) ;
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Sandmaier, Brenda M. (Fred Hutchinson Cancer Research Center) ;
de Lima, Marcos (University Hospitals Case Medical Center) ;
Kebriaei, Partow (The University of Texas MD Anderson Cancer Center) ;
Litzow, Mark (Mayo Clinic.) ;
Saber, Wael (Medical College of Wisconsin) ;
Weisdorf, Daniel (University of Minnesota) ;
Universitat Autònoma de Barcelona
Optimal post-remission therapy for adolescents and young adults (AYAs) with Ph-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is not established. We compared overall survival (OS), disease-free survival (DFS), relapse, and non-relapse mortality (NRM) for patients receiving post-remission therapy on CALGB 10403 to a cohort undergoing myeloablative (MA) allogeneic hematopoietic cell transplantation (HCT) in CR1. [...]
2021 - 10.1038/s41375-021-01213-5
Leukemia, Vol. 35 (march 2021) , p. 2076-2085
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
